KSQ Therapeutics
www.ksqtx.com
Latest From KSQ Therapeutics
David Or Goliath: Where Is Innovation Winning Through?
With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.
Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.
Finance Watch: Government Grants Galore And Other New Funding Sources
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Immune Disorders
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Start-Up
- Parent & Subsidiaries
- KSQ Therapeutics
- Senior Management
-
David Meeker, MD, CEO
John Trzupek, PhD, Interim CFO & Head, Corp. Dev.
Frank Stegmeier, PhD, CSO - Contact Info
-
KSQ Therapeutics
Phone: (617) 674-9150
610 Main St. North
4th Fl.
Cambridge, MA 02139
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice